A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind,
placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a
monotherapy for Major Depressive Disorder.